|
HMGB2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.75359999998737E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.28549999997863E-06 |
| Normal-vs-Stage2 |
1.79860004667631E-09 |
| Normal-vs-Stage3 |
3.68529999994482E-06 |
| Normal-vs-Stage4 |
1.468030E-02 |
| Stage1-vs-Stage2 |
1.360590E-03 |
| Stage1-vs-Stage3 |
5.689000E-01 |
| Stage1-vs-Stage4 |
3.053600E-02 |
| Stage2-vs-Stage3 |
1.227630E-02 |
| Stage2-vs-Stage4 |
2.14729999999941E-05 |
| Stage3-vs-Stage4 |
2.267500E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.94234999999487E-05 |
| Normal-vs-AfricanAmerican |
1.102360E-02 |
| Normal-vs-Asian |
3.150900E-04 |
| Caucasian-vs-AfricanAmerican |
7.101000E-01 |
| Caucasian-vs-Asian |
8.191200E-01 |
| AfricanAmerican-vs-Asian |
8.520800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.65575999999668E-05 |
| Normal-vs-Female |
1.22280000003361E-06 |
| Male-vs-Female |
4.777600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.86850000000383E-05 |
| Normal-vs-Age(41-60Yrs) |
6.56520000030802E-07 |
| Normal-vs-Age(61-80Yrs) |
1.39679999999753E-06 |
| Normal-vs-Age(81-100Yrs) |
2.853200E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.476240E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.807200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.068800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.746000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.169980E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.048800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.471600E-01 |
| Classical-VS-Follicular |
3.56439999960045E-07 |
| Classical-VS-Other |
4.752400E-01 |
| Classical-VS-Normal |
9.53639999999867E-05 |
| Tall-VS-Follicular |
7.570900E-04 |
| Tall-VS-Other |
6.035000E-01 |
| Tall-VS-Normal |
3.180100E-03 |
| Follicular-VS-Other |
1.663760E-02 |
| Follicular-VS-Normal |
8.15639999984796E-10 |
| Other-VS-Normal |
2.846800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.62720000093952E-08 |
| Normal-vs-N1 |
1.840020E-04 |
| N0-vs-N1 |
5.629700E-02 |
|
|
